Month: December 2022

As technological innovation continues to integrate into everyday functionalities, investors ought to consider the hottest augmented reality stocks to own for 2023 and beyond. To get everyone on the same page, AR refers to platforms that overlay “visual, auditory, or other sensory information onto the real world to enhance one’s experience,” per Investopedia. It’s another
0 Comments
Klaus Vedfelt Back in November, we told you we were taking some profit, and selling some covered calls in AT&T Inc. (NYSE:T) stock after the amazing run that it had following our big wave of buying when the stock fell under $15. Solid trade, but we also keep T and competitor Verizon (VZ) in our
0 Comments
Some of the hottest biotech stocks are safe and recession-proof. After all, we can’t stop people from aging – at least, not yet. We can’t stop people from seeking treatments for a myriad of issues. Plus, there’s growing demand for innovation in gene therapies, immune-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical
0 Comments
JHVEPhoto/iStock Editorial via Getty Images Dear readers/followers In this article, I want to give you the opportunity to learn about the updated valuation of an insurance business – Chubb (NYSE:CB). As you may know from my articles, I’m big on investing in financials and insurance businesses specifically, because they come with such conservative and excellent
0 Comments
Major indices such as the S&P 500 and the Nasdaq Composite may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of those areas is among the hottest healthcare stocks. With company-specific catalysts outweighing negative macro factors such as high inflation, rising interest rates, and slowing economic growth, scores
0 Comments
MediaProduction Author’s Note: This is an abbreviated version of an article originally published in advance inside Integrated BioSci Investing for our members. Intra-Cellular The intelligent investor is a realist who sells to optimists and buys from pessimists. – Ben Graham (Warren Buffett’s mentor) In biotech investing, you should not expect growth to occur linearly. Instead,
0 Comments
There are plenty of microchip producers you can invest in. However, Satixfy Communications (NYSE:SATX) is quite different from the rest of them. SATX stock earns a “B” rating because there’s definitely risk involved, but Satixfy appears to be pioneering a specific market with growth potential. Satixfy Communications is an Israel-based satellite communications component maker. The
0 Comments
Kevin Dietsch In a recent report, I discussed the quarterly results of Aerojet Rocketdyne (NYSE:AJRD) and marked shares of Aerojet Rocketdyne a buy due to their strategic positioning for weapon system capability and national security as well as space exploration. Reuters reported that L3Harris Technologies (LHX) is close to announcing the acquisition of Aerojet Rocketdyne
0 Comments
In this article NCLH MRNA ORCL PINS Follow your favorite stocksCREATE FREE ACCOUNT Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. Dado Ruvic | Reuters Check out the companies making headlines in midday trading. Moderna – The drugmaker saw its stock soar 19.6% after
0 Comments
Is it always a good thing when a company’s management is ultra-confident? Not necessarily, when it comes to Intel (NASDAQ:INTC) stock. Some traders and analysts aren’t fully convinced that the chipmaker can recover its lost ground in 2023. Before jumping into the trade, take a serious look at Intel’s headwinds and consider sitting on the sidelines
0 Comments
Recently, I begged people not to invest in video game retailer GameStop (NYSE:GME) yet. I suggested that GME stock needs to hit $20 before anyone should jump into the trade. Even after a post-earnings rally, I’m standing by the wait-for-$20 strategy as GameStop’s financials aren’t as stellar as some perma-bulls might assume. Don’t get me wrong
0 Comments